AstraZeneca (AZN.US) Q3 profit growth exceeds expectations, with oncology drugs driving the increase

According to Golden Ten Data APP, AstraZeneca (AZN.US) released its third-quarter 2026 financial results on October 30. At constant exchange rates (CER), total revenue for the quarter increased by 7% year-on-year to $16.209 billion; product sales reached $15.066 billion, up 5%; alliance revenue was $1.107 billion, up 36%. Core earnings per share were $2.79, an increase of 19% year-on-year; reported earnings per share were $2.02, up 26%. According to estimates compiled by MarketBeat, the market had originally expected core earnings per share of $2.60 and revenue of $16.0 billion for the quarter, which the actual results exceeded by approximately 7% and 1% respectively.